HUTCHMED (China) Limited (AIM:HCM)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.88B -5.0% |
| Revenue (ttm) | 413.87M -8.8% |
| Net Income | 13.48M -96.2% |
| EPS | 0.02 -96.2% |
| Shares Out | 869.07M |
| PE Ratio | 141.94 |
| Forward PE | 27.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,846 |
| Open | 209.00 |
| Previous Close | 210.00 |
| Day's Range | 207.00 - 216.00 |
| 52-Week Range | 150.50 - 247.30 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 347.89 (+61.06%) |
| Est. Earnings | Nov 13, 2026 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet... [Read more]
Financial Performance
In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HCM stock is "Buy." The 12-month stock price target is 348p, which is an increase of 61.06% from the latest price.
News
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from sever...
Hutchmed price target raised to $18 from $16 at BofA
BofA raised the firm’s price target on Hutchmed (HCM) to $18 from $16 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past month,…
HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100
HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100
Hutchmed upgraded to Buy from Hold at HSBC
HSBC upgraded Hutchmed (HCM) to Buy from Hold with a HK$17.40 price target
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The t...
Hutchmed upgraded to Buy from Hold at Daiwa
Daiwa analyst Jing Yang upgraded Hutchmed (HCM) to Buy from Hold with an $18.50 price target The firm views the company’s commercialization agreement with GSK as a “major positive surprise.”…
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.
HUTCHMED (China) Transcript: Status update
A major licensing and co-development deal with GSK for HMPL-A830 accelerates global development and validates the ATTC platform, with HUTCHMED leading phase I trials and GSK taking ex-China rights. The agreement includes $1.3 billion in potential value and tiered royalties.
HUTCHMED (China) Press release: Status update
HUTCHMED (China) issued a press release on September 3, 2026, disclosing material business information to investors.
HUTCHMED (China) Slides: Status update
HUTCHMED (China) has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Hutchmed, GSK enter HMPL-A830 commercialization agreement
Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK (GSK), granting the GSK subsidiary worldwide ri...
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker ...
HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%
(RTTNews) - HUTCHMED (China) Limited (HCM), a precision oncology-focused company, on Thursday announced that its subsidiary HUTCHMED Limited has entered into an exclusive development and license agree...
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p....
HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC
(RTTNews) - HUTCHMED (China) Ltd (HCM) announced results from the Phase III SANOVO China trial, evaluating ORPATHYS plus TAGRISSO, showing statistically significant and clinically meaningful improveme...
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the estab...
Hutchmed's ATLED Wins Conditional Approval From NMPA For Intrahepatic Cholangiocarcinoma
(RTTNews) - Hutchmed (China) Limited (HCM) on Friday announced that the Chinese National Medical Products Administration (NMPA) has granted conditional approval for ATLED's New Drug Application (NDA)....
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China Novel, highly potent oral selective FGFR 1/2/3 inhib...
HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial
(RTTNews) - HUTCHMED (China) Ltd (HCM), a commercial-stage company, announced positive results from the SAFFRON Phase III trial evaluating ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in patient...
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
Hutchmed (HCM) announces that positive high-level results from the Saffron Phase III trial showed Orpathys plus Tagrisso demonstrated a statistically significant and clinically meaningful improvement ...
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
HUTCHMED H1 Earnings Call Highlights
HUTCHMED NASDAQ: HCM reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported re...
HUTCHMED (China) Earnings Call Transcript: H1 2026
Strong first-half growth driven by China and ex-U.S. oncology sales, with robust pipeline progress including ATTC assets and Sovleplenib. Guidance maintained, profitability achieved, and significant cash reserves support continued R&D and commercial expansion.
HUTCHMED (China) Quarterly report: H1 2026
HUTCHMED (China) has published its H1 2026 quarterly earnings report on July 30, 2026.